Aurobindo Pharma Legal & Regulatory

Aurobindo Pharma Board Meeting Date

Aurobindo Pharma's board meets 4 November 2026 to consider Q2 and half-year results and a possible interim dividend. Trading window stays closed until 6 November.

Aurobindo Pharma Other Announcement

Aurobindo Pharma Ltd has filed its quarterly shareholding pattern for the period ended September 30, 2026, as mandated by SEBI regulations.

Aurobindo Pharma Business Update

Aurobindo Pharma received USFDA final approval for Perampanel Tablets in multiple strengths. The product will be manufactured by its subsidiary and launched in Q3FY27.

Aurobindo Pharma Acquisition

Aurobindo Pharma's subsidiary, Apitoria Pharma, has completed the acquisition of the Contract Research Services business of A1 Biochem Group. The deal integrates CRO capabilities into Apitoria's operations.

Aurobindo Pharma Acquisition Worth ₹146.4 Cr

Aurobindo Pharma's subsidiary acquired 100% ownership of US-based A1 Biochem Labs LLC for USD 15.247 million in an all-cash deal.

Value

₹146.4 Cr

Aurobindo Pharma Merger & Restructuring Worth ₹33.8 Cr

Aurobindo Pharma's subsidiary, Apitoria Pharma, completed a 20% stake dilution in A1 Biochem Labs. Dr. Rajendra Gadikota subscribed to securities worth ₹33.80 Crore.

Value

₹33.80 Cr

Coromandel International Legal & Regulatory

Coromandel International received a Deputy Commissioner (Appeal) GST order-in-appeal for FY 2019-20 confirming ineligible input tax credit demand. The company will appeal before GSTAT and expects no significant financial impact.

Value

₹0.18 Cr

Taurian Mps Legal & Regulatory

Taurian MPS received a SEBI adjudication order imposing penalties of Rs.5 lakh on the company, Rs.5 lakh on promoters jointly, and Rs.8 lakh on the merchant banker. The penalties relate to IPO offer document disclosure deficiencies.

Value

₹0.05 Cr

Coromandel International Legal & Regulatory

Coromandel International received a GST Order-in-Appeal confirming a ₹1.79 Crore tax demand. Including interest and penalty, the total is ₹4.05 Crore; the company will appeal.

Value

₹4.05 Cr

Shreeji Global FMCG Legal & Regulatory

Shreeji Global FMCG received a customs Order-in-Original demanding about ₹42.47 Crore in duty, penalties and redemption fines. The company plans to appeal before CESTAT.

Value

₹42.47 Cr

HD Fire Protect Legal & Regulatory

HD Fire Protect received an MPCB refusal of Consent to Operate for its Jalgaon expansion sheds. Existing manufacturing operations continue, with no material impact anticipated.

Krishna Institute of Medical Sciences Legal & Regulatory

KIMS discloses a pending suit over its Chennai hospital land lease, naming it defendant. Supreme Court dismissed its SLP; no injunction halts the project.